J07BK01 - Varicella, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can lead to a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.
Side effects
Fever is reported as a very common side effect of the varicella vaccine.
Rationale
Based on the pharmacokinetics of the varicella, live attenuated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live attenuated varicella virus.
Therapeutic characteristics
The varicella vaccine is indicated for active immunization against varicella in individuals from 12 months of age. The vaccine is administered by two intramuscular or subcutaneous injections.
Metabolism and pharmacokinetics
The varicella vaccine is not metabolized by the cytochrome P450 system.
References
- Government bodies
- Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Varivax. (Last edition: November. 2013). #1883
Similar drugs
© NAPOS 2024